|1.||Iskandrian, Ami E: 12 articles (04/2013 - 12/2005)|
|2.||Cerqueira, Manuel D: 8 articles (10/2014 - 07/2004)|
|3.||Doukky, Rami: 7 articles (10/2015 - 06/2012)|
|4.||Heo, Jaekyeong: 7 articles (04/2013 - 04/2009)|
|5.||Belardinelli, Luiz: 7 articles (02/2012 - 01/2003)|
|6.||Hage, Fadi G: 5 articles (04/2013 - 04/2009)|
|7.||Blankstein, Ron: 4 articles (03/2015 - 10/2012)|
|8.||Feaheny, Kathleen: 4 articles (03/2015 - 04/2012)|
|9.||Ananthasubramaniam, Karthik: 4 articles (03/2014 - 08/2011)|
|10.||Mahmarian, John J: 4 articles (12/2013 - 12/2005)|
|1.||Coronary Artery Disease (Coronary Atherosclerosis)
10/01/2013 - "Our objective was to study the diagnostic performance of regadenoson (82)Rb myocardial perfusion PET imaging to detect obstructive coronary artery disease (CAD). "
01/01/2013 - "The aim of this study was to determine the prognostic value of a normal regadenoson perfusion CMR in patients with known or suspected coronary artery disease. "
01/01/2016 - "We report the case of dynamic ST-segment elevation electrocardiogram changes after regadenoson injection during an inpatient single-photon emission computed tomography myocardial perfusion stress test, with subsequent coronary angiography revealing the presence of hemodynamically significant coronary artery disease. "
06/01/2015 - "The significance of automatically measured transient ischemic dilation in identifying severe and extensive coronary artery disease in regadenoson, single-isotope technetium-99m myocardial perfusion SPECT."
10/15/2014 - "Risk stratification by regadenoson stress magnetic resonance imaging in patients with known or suspected coronary artery disease."
|2.||Kidney Diseases (Kidney Disease)
08/01/2011 - "Pharmacokinetic studies suggest delayed clearance of Regadenoson (REG), a new selective A2A receptor agonist in chronic kidney disease (CKD). "
04/01/2012 - "A randomized, double-blind, placebo-controlled study of the safety and tolerance of regadenoson in subjects with stage 3 or 4 chronic kidney disease."
10/01/2015 - "Patients with severe chronic kidney disease (CKD) experience more frequent gastrointestinal adverse effects (AE) from regadenoson. "
04/01/2012 - "The safety and tolerability of regadenoson, a pharmacologic stress agent that is excreted primarily by the kidneys, were examined in subjects with chronic kidney disease (CKD). "
08/01/2011 - "Safety of regadenoson as a pharmacologic stress agent for myocardial perfusion imaging in chronic kidney disease patients not on hemodialysis."
07/01/2007 - "This study characterized the dose dependence of regadenoson-induced coronary hyperemia. "
04/01/2015 - "Does a shortened hyperemia with regadenoson stress pose a concern for quantitative Rb-82 PET imaging? "
02/01/2013 - "Regadenoson has advantages of a fixed dose and favorable symptom profile, but its mean maximal hyperemia is only 2.3 minutes. "
10/01/2012 - "Regadenoson during exercise stress test (ETT) can provide maximal hyperemia for myocardial perfusion imaging (MPI), along with exercise information. "
01/01/2012 - "Twenty healthy subjects underwent CMR perfusion imaging during resting conditions, during regadenoson-induced hyperemia (0.4 mg), and after 15 min of recovery. "
|4.||Coronary Stenosis (Coronary Artery Stenosis)
04/01/2012 - "This study assessed the haemodynamic profile and ability of regadenoson, a novel selective A(2A) receptor agonist, to detect coronary artery stenosis during myocardial contrast echocardiography. "
01/01/2015 - "Regadenoson-Stress Dynamic Myocardial Perfusion Improves Diagnostic Performance of CT Angiography in Assessment of Intermediate Coronary Artery Stenosis in Asymptomatic Patients."
04/01/2012 - "Regadenoson can be used as a vasodilator stress agent with myocardial contrast echocardiography to detect the presence of physiologically significant coronary stenosis. "
04/01/2012 - "Myocardial contrast echocardiography was performed to measure myocardial blood volume, myocardial blood flow velocity, and total regional myocardial blood flow before and after administration of regadenoson (5 µg kg(-1), 10 s bolus) in 10 open-chest dogs with mild-to-moderate coronary stenosis that was not flow limiting at rest. "
11/01/2011 - "Regadenoson real-time myocardial contrast echocardiography appears to be a feasible, safe, and rapid noninvasive method for the detection of significant coronary artery stenoses."
|5.||Chronic Obstructive Pulmonary Disease (COPD)
01/01/2014 - "The literature describing the experience with regadenoson in COPD patients, though limited, is rapidly growing and reassuring. "
01/01/2014 - "Regadenoson use in patients with chronic obstructive pulmonary disease: the state of current knowledge."
01/01/2014 - "We observed no significant changes in BP among either group, but there was a tendency towards a higher increase in systolic BP in COPD patients following regadenoson administration (148.3 ± 27.6 vs. 154.6 ± 31.0 mmHg, p = 0.056). "
05/01/2008 - "This pilot study showed the overall safety of regadenoson in 49 compromised outpatients with clinically stable moderate and severe chronic obstructive pulmonary disease."
08/01/2012 - "A randomized, double-blind, placebo-controlled study assessing the safety and tolerability of regadenoson in subjects with asthma or chronic obstructive pulmonary disease."
|4.||Adenosine A2A Receptor (Adenosine A2A Receptors)
|6.||Purinergic P1 Receptors (Adenosine Receptor)
|7.||Cytidine Triphosphate (CTP)
|9.||Blood Glucose (Blood Sugar)
|2.||Activities of Daily Living (ADL)
|3.||Renal Dialysis (Hemodialysis)